FIELD: medicine, oncology. SUBSTANCE: invention relates to methods of inhibition of tumor cell proliferation. Method involves making syndecane ectodomain concentration in extracellular medium of indicated cell equal to 0.7-1 nM. Invention proposes also the pharmaceutical composition containing syndicane ectodomain as an active component that can be used for tumor treatment. EFFECT: enhanced effectiveness of suppression of malignant cells proliferation. 22 cl, 13 dwg, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF DETECTION OF MALIGNANCY | 1991 |
|
RU2139540C1 |
| HUMANIZED MONOCLONAL ANTIBODY SPECIFIC TO SYNDECAN-1 | 2015 |
|
RU2611685C2 |
| HUMANISED MONOCLONAL ANTIBODY SPECIFIC TO SYNDECAN-1 | 2013 |
|
RU2551235C2 |
| INSULIN-LIKE GROWTH FACTOR I RECEPTOR ANTIBODIES AND USING THEM | 2007 |
|
RU2541765C2 |
| METHOD TO TREAT α-GALACTOSIDASE A DEFICIENCY | 1997 |
|
RU2179034C2 |
| SELF-AMPLIFYING PHARMACOLOGICALLY CONTROLLABLE EXPRESSIVE SYSTEMS | 1997 |
|
RU2197993C2 |
| ENHANCEMENT OF IMMUNE RESPONSE WHEREIN FUSED PROTEIN ANTIBODY-CYTOKINE IS MEDIATOR BY COMBINED TREATMENT WITH AGENTS INCREASING IMMUNOCYTOKINE ABSORPTION | 2001 |
|
RU2272644C2 |
| ISOLATED NUCLEIC ACID ENCODING POLYPEPTIDE TAG 7, ISOLATED POLYPEPTIDE TAG 7, METHOD FOR INHIBITION OF TUMOR DEVELOPMENT IN MAMMALS (VARIANTS) AND METHOD FOR TREATMENT OF CANCER IN ANIMAL (VARIANTS) | 1998 |
|
RU2238976C2 |
| HYBRID MATRIX IMPLANTS AND EXPLANTS | 1996 |
|
RU2201765C2 |
| FUSED PROTEINS WITH IMMUNOGLOBULIN FC-FRAGMENT FOR ENHANCING IMMUNOGENICITY OF PROTEIN AND PEPTIDE ANTIGENS | 2000 |
|
RU2248214C2 |
